{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:58Z","timestamp":1791489658544,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":270,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101458","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:20:47Z","timestamp":1790886047000},"page":"101458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-coding RNAs as mediators of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: a scoping review"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7827-5250","authenticated-orcid":false,"given":"Diana Marcela","family":"Cuervo - Lozada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-7241","authenticated-orcid":false,"given":"Alexander","family":"Casallas-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101458_bib0002","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101458_bib0003","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101458_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood.2024026508","article-title":"How I individualize frontline treatment for chronic-phase CML","volume":"147","author":"Leyte-Vidal","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101458_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101458_bib0006","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101458_bib0007","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101458_bib0008","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101458_bib0009","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101458_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized bfore trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101458_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101458_bib0012","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-024-02353-0","article-title":"Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib","volume":"38","author":"Leyte-Vidal","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101458_bib0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.2024026511","article-title":"How I evaluate and treat resistance and relapse in CML","volume":"147","author":"Soverini","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101458_bib0014","article-title":"Non-coding RNAs: emerging contributors to chemoresistance in chronic myeloid leukemia","volume":"23","author":"Ghadyaninejhad","year":"2025","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.ctarc.2026.101458_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/frnar.2024.1334464","article-title":"Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia","volume":"2","author":"Dutta","year":"2024","journal-title":"Front RNA Res."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101458_bib0016","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1002\/cam4.6027","article-title":"Long non-coding RNAs regulate treatment outcome in leukemia: what have we learnt recently?","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101458_bib0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/bfgp\/elv059","article-title":"Noncoding RNAs and their functional involvement in regulation of chronic myeloid leukemia","volume":"15","author":"Wang","year":"2016","journal-title":"Brief. Funct. Genomics."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0018","article-title":"MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa","volume":"15","author":"Urgessa","year":"2025","journal-title":"Ethiopia. Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101458_bib0019","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.omtn.2020.01.021","article-title":"The identification of long non-coding RNA H19 target and its function in chronic myeloid leukemia","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic. Acids."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101458_bib0020","article-title":"miRNA expression based modulation: a new paradigm for the treatment of chronic myeloid leukemia","volume":"1880","author":"Ansari","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101458_bib0021","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/jasms.3c00103","article-title":"Analysis of the inhibitory effect of hsa-miR-145-5p and hsa-miR-203a-5p on imatinib-resistant K562 cells by GC\/MS metabolomics method","volume":"34","author":"Singh","year":"2023","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101458_bib0022","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.3390\/ijms26136533","article-title":"Identification of a PAK6-mediated MDM2\/p21 axis that modulates survival and cell cycle control of drug-resistant stem\/progenitor cells in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101458_bib0023","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.2019003636","article-title":"The miR-185\/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101458_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012271","article-title":"Non-coding RNAs are implicit in chronic myeloid leukemia therapy resistance","volume":"23","author":"Rudich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101458_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120437","article-title":"The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance","volume":"296","author":"Navabi","year":"2022","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101458_bib0026","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41419-021-04209-2","article-title":"Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance","volume":"12","author":"Wu","year":"2021","journal-title":"Cell Death. Dis."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101458_bib0027","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02838-7","article-title":"Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1\/2 activation in chronic myeloid leukemia cells","volume":"42","author":"Tsubaki","year":"2025","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101458_bib0028","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000524158","article-title":"miR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukaemia cells to imatinib by inhibiting mTOR signalling","volume":"145","author":"Liu","year":"2022","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2379597","article-title":"Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p\/SENP2\/PI3K\/AKT\/mTOR axis","volume":"29","author":"Jiang","year":"2024","journal-title":"Hematol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101458_bib0030","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/s41375-023-02062-0","article-title":"Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis","volume":"37","author":"Wu","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101458_bib0031","first-page":"8881","article-title":"Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB","volume":"13","author":"Zhu","year":"2022","journal-title":"Bioeng."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0032","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-023-05036-8","article-title":"miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1","volume":"81","author":"Zhang","year":"2024","journal-title":"Cell Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101458_bib0033","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5339","article-title":"TRIB2 regulates the expression of miR-33a-5p through the ERK\/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells","volume":"60","author":"Sun","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ctarc.2026.101458_bib0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exphem.2022.12.003","article-title":"miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells","volume":"118","author":"Rittavee","year":"2023","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101458_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331479","article-title":"Exosomal miRNA expression profiling in patients with imatinib resistant chronic myeloid leukemia: a pilot study","volume":"20","author":"Navakanitworakul","year":"2025","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101458_bib0036","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1007\/s00210-024-03198-1","article-title":"Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia","volume":"397","author":"Karabay","year":"2024","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-021-00395-z","article-title":"Global identification of circular RNAs in imatinib resistance of chronic myeloid leukemia by modulating signaling pathways of circ_0080145\/miR-203\/ABL1 and circ_0051886\/miR-637\/ABL1","volume":"27","author":"Lu","year":"2021","journal-title":"Mol. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101458_bib0038","first-page":"478","article-title":"and formally published in print volume 39(7), 2024; cited by print date, consistent with the MEDLINE record. 38. Che H, Ding H, Jia X. circ_0080145 enhances imatinib resistance of chronic myeloid leukemia by regulating miR-326\/PPFIA1 axis","volume":"39","author":"Che","year":"2024","journal-title":"Cancer BiOther Radiopharm."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03586-2","article-title":"circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation","volume":"20","author":"Wang","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101458_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147917","article-title":"circ_SIRT1 upregulates ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3","volume":"893","author":"Zhang","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.ctarc.2026.101458_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.153012","article-title":"Exosomal circ_0058493 promotes imatinib resistance via miR-548b-3p\/U2SURP axis in CML cells","volume":"793","author":"Tang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ctarc.2026.101458_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106838","article-title":"LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients","volume":"116","author":"Shehata","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ctarc.2026.101458_bib0043","first-page":"4","article-title":"Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to imatinib via cell cycle signaling pathway","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctarc.2026.101458_bib0044","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211052150","article-title":"LncRNA OIP5-AS1 promotes the autophagy-related imatinib resistance in chronic myeloid leukemia cells by regulating miR-30e-5p\/ATG12 axis","volume":"20","author":"Dai","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101458_bib0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematol"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101458_bib0046","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101458_bib0047","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ajh.26556","article-title":"Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success","volume":"97","author":"Inzoli","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101458_bib0048","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101458_bib0049","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101458_bib0050","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101458_bib0051","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/ejh.70000","article-title":"Treatment-free remission in chronic myeloid leukemia: revisiting the 'W' questions","volume":"115","author":"Bruzzese","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101458_bib0052","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41375-022-01680-4","article-title":"Identification of key microRNAs as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial","volume":"36","author":"Yen","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0053","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101458_bib0054","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2304488","article-title":"Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment","volume":"29","author":"Guo","year":"2024","journal-title":"Hematol."},{"key":"10.1016\/j.ctarc.2026.101458_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110038","article-title":"AKR1C3 decreased CML sensitivity to imatinib in bone marrow microenvironment via dysregulation of miR-379-5p","volume":"84","author":"Pan","year":"2021","journal-title":"Cell Signal."},{"key":"10.1016\/j.ctarc.2026.101458_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.bglo.2026.100155","article-title":"Epidemiology, treatment patterns and survival of chronic myeloid leukemia in Colombia: a real-world cohort study (2018-2023)","author":"Bola\u00f1os-Lopez","year":"2026","journal-title":"Blood Global Hematol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101458_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.bglo.2026.100069","article-title":"Chronic myeloid leukemia in Mexico: 2 decades of experience at the Hospital Central Militar","volume":"2","author":"Garc\u00eda-Castillo","year":"2026","journal-title":"Blood Global Hematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:40:44Z","timestamp":1791488444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":57,"alternative-id":["S2468294226003680"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101458","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-coding RNAs as mediators of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101458"}}